NO975322L - Flytende hydrokarbonemulsjon som et vaskulært nitrogenoksydreservoar - Google Patents

Flytende hydrokarbonemulsjon som et vaskulært nitrogenoksydreservoar

Info

Publication number
NO975322L
NO975322L NO975322A NO975322A NO975322L NO 975322 L NO975322 L NO 975322L NO 975322 A NO975322 A NO 975322A NO 975322 A NO975322 A NO 975322A NO 975322 L NO975322 L NO 975322L
Authority
NO
Norway
Prior art keywords
nitric oxide
liquid hydrocarbon
hydrocarbon emulsion
oxide reservoir
vascular nitric
Prior art date
Application number
NO975322A
Other languages
English (en)
Other versions
NO975322D0 (no
Inventor
Stephen F Flaim
Original Assignee
Alliance Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alliance Pharma filed Critical Alliance Pharma
Publication of NO975322D0 publication Critical patent/NO975322D0/no
Publication of NO975322L publication Critical patent/NO975322L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Biokompatlble fluorkarbonemulsjoner benyttes for å inhibere fjerning av endogent-produsert nitrogenoksyd fra blodstrømmen og for derved å Inhibere vaskulær stenose, vasokonstriksjon og enhver annen fysiologisk tilstand eller mangel som helt eller delvis stammer fra en mangel på endogent nitrogenoksyd. Flytende fluorkarbonemulsjoner benyttes også for å forbedre effektiviteten ved intravenøst administrert hemoglobin ved å begrense tilgjengeligheten av met- hemoglobin som danner plasma-oppløst nitrogenoksyd.
NO975322A 1995-06-07 1997-11-19 Flytende hydrokarbonemulsjon som et vaskulært nitrogenoksydreservoar NO975322L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/501,976 US5726209A (en) 1995-06-07 1995-06-07 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir
PCT/US1996/009549 WO1996040058A2 (en) 1995-06-07 1996-06-07 Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir

Publications (2)

Publication Number Publication Date
NO975322D0 NO975322D0 (no) 1997-11-19
NO975322L true NO975322L (no) 1998-01-09

Family

ID=23995789

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975322A NO975322L (no) 1995-06-07 1997-11-19 Flytende hydrokarbonemulsjon som et vaskulært nitrogenoksydreservoar

Country Status (12)

Country Link
US (1) US5726209A (no)
EP (1) EP0831776A2 (no)
JP (1) JPH11507351A (no)
KR (1) KR19990022586A (no)
CN (1) CN1192136A (no)
AU (1) AU718120B2 (no)
CA (1) CA2221965A1 (no)
HU (1) HUP9900900A2 (no)
IL (1) IL122261A (no)
NO (1) NO975322L (no)
PL (1) PL323821A1 (no)
WO (1) WO1996040058A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
US6103275A (en) * 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
RU2161122C1 (ru) * 1999-09-10 2000-12-27 Институт молекулярной генетики РАН Способ ускорения окисления оксида азота (no) в гетерогенной среде
CN101646442B (zh) * 2007-02-23 2013-09-04 21世纪国际新技术株式会社 血管痉挛的治疗剂或预防剂
US8906855B2 (en) 2007-12-22 2014-12-09 Vivacelle Bio, Inc. Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
US8618056B2 (en) 2007-12-22 2013-12-31 Cuthbert O. Simpkins Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
CN102300555B (zh) * 2009-01-30 2015-06-17 卡斯伯特·O·辛普金斯 复苏液

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US4781676A (en) * 1987-02-20 1988-11-01 Air Products And Chemicals, Inc. Interstitial administration of perfluorochemical emulsions for reoxygenation of hypoxic tumor cells
US4895876A (en) * 1987-03-20 1990-01-23 Air Products And Chemicals, Inc. Concentrated stable fluorochemical aqueous emulsions containing triglycerides
US4866096A (en) * 1987-03-20 1989-09-12 Air Products And Chemicals, Inc. Stable fluorochemical aqueous emulsions
US4993415A (en) * 1988-08-19 1991-02-19 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US5536241A (en) * 1990-12-05 1996-07-16 The General Hospital Corporation Methods and devices for relaxing smooth muscle contractions
EP0663821A4 (en) * 1991-08-08 1997-09-17 Leigh D Segel BLOOD REPLACEMENT WITH FLUORINE.
US5628930A (en) * 1992-10-27 1997-05-13 Alliance Pharmaceutical Corp. Stabilization of fluorocarbon emulsions
WO1995010267A1 (en) * 1993-10-08 1995-04-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of nitric oxide-releasing compounds as hypoxic cell radiation sensitizers
ES2149338T3 (es) * 1993-11-02 2000-11-01 Us Health Utilizacion de compuestos que liberan oxido nitrico para la fabricacion de un medicamento destinado al tratamiento de lesiones por reperfusion isquemica.

Also Published As

Publication number Publication date
HUP9900900A2 (hu) 1999-08-30
AU718120B2 (en) 2000-04-06
PL323821A1 (en) 1998-04-27
IL122261A0 (en) 1998-04-05
US5726209A (en) 1998-03-10
CA2221965A1 (en) 1996-12-19
CN1192136A (zh) 1998-09-02
WO1996040058A3 (en) 1997-02-13
MX9709695A (es) 1998-06-28
KR19990022586A (ko) 1999-03-25
EP0831776A2 (en) 1998-04-01
NO975322D0 (no) 1997-11-19
IL122261A (en) 2001-09-13
AU6161596A (en) 1996-12-30
WO1996040058A2 (en) 1996-12-19
JPH11507351A (ja) 1999-06-29

Similar Documents

Publication Publication Date Title
Daram et al. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review
Ho Hemodialysis membranes: interleukins, biocompatibility, and middle molecules
Waring et al. Uric acid as a risk factor for cardiovascular disease
LaMuraglia et al. Carotid endarterectomy at the millennium: what interventional therapy must match
Spiess Perfluorocarbon emulsions as a promising technology: a review of tissue and vascular gas dynamics
Spiegel et al. Long‐term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study
DK0865294T3 (da) Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
NO20050827L (no) Anvendelse av interferon-B ved behandling av nyresvikt
NO975322L (no) Flytende hydrokarbonemulsjon som et vaskulært nitrogenoksydreservoar
WO2005013947A3 (en) Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer
Barboriak et al. Coronary artery occlusion and blood lipids
ATE313802T1 (de) Bestimmung von adrenomedullin-bindenden proteinen
JP2015013887A (ja) アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法
CY1105545T1 (el) Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας
WO2022023566A3 (en) Cd-3 antibodies for the treatment of coronavirus
Pires et al. Engineering therapeutics to detoxify hemoglobin, heme, and iron
Xiang et al. Extremity trauma exacerbates acute kidney injury following prolonged hemorrhagic hypotension
Ivashkova et al. Bradykinin B2 receptor antagonism with LF 18-1505T reduces brain edema and improves neurological outcome after closed head trauma in rats
Gauthier et al. Cyclosporine avoidance
Tanaka et al. In vitro effects of antihypertensive drugs on thromboxane agonist (U46619)-induced vasoconstriction in human internal mammary artery
Kinoshita et al. Preoperative renal dysfunction and mortality after off-pump coronary artery bypass grafting in Japanese
FRANCO et al. Fibroblastic growth factor and infarct size
Pupovac et al. Factor eight inhibiting bypass activity for refractory bleeding in acute type A aortic dissection repair: A propensity‐matched analysis
Vasugi et al. Systemic lupus erythematosis with antiphospholipid antibody syndrome: A mimic of Buerger′ s disease
Den Hollander New insights in the pathophysiology of burns: implications for the prevention of wound progression: SA Burn Society Congress

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application